Skip to content
Characterizing the Immunome at Scale episode artwork

Apr 29, 2021 23 min

Characterizing the Immunome at Scale

from The Bio Report Hosted by Levine Media Group

When variants of the COVID-19 virus emerged in late 2020, it raised concerns about whether people already infected with the original virus, or vaccinated against it, would be able to generate a protective immune response that would confer protection against these new strains. Researchers at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and Johns Hopkins University recently reported encouraging findings from a study that took a detailed look at the antibodies in the blood from COVID-19 patients. To do this, they used a deep immunomics technology platform developed by ImmunoScape. We spoke to Brian Abel, senior director of business development at ImmunoScape and lead of the company’s COVID-19 Vaccine Task Force, about the COVID-19 study, the company’s technology, and how it is being used to develop the next generation of immunotherapies.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Characterizing the Immunome at Scale

0:00 23:51

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 23 minutes long.

When was this The Bio Report episode published?

This episode was published on April 29, 2021.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.